CGEN
HealthcareCompugen Ltd.
$1.52
$-0.03 (-1.94%)
Jan 5, 2026
Price History (1Y)
Analysis
Compugen Ltd. is a biotechnology company operating in the healthcare sector with a market capitalization of $143.08M and approximately 74 employees. The company's revenue over the trailing twelve months (TTM) was $6.90M. The financial health of Compugen Ltd. reveals significant profitability challenges, as indicated by its negative net income ($-27,619,000) and EBITDA (-$31,706,500). Margins are also concerning: gross margin is 7.4%, operating margin is -417.4%, and profit margin is 0.0%. The company's returns on equity and assets are equally unimpressive at -53.0% and -18.2%, respectively. Compugen Ltd.'s balance sheet shows a manageable debt level of $2.95M compared to its cash position, which stands at $86.09M. The valuation context for Compugen Ltd. is marked by an unfavorable forward P/E ratio of -4.83, indicating that the company's current stock price does not reflect future earnings expectations. The price to sales ratio is 20.73, and the price to book ratio is 3.24. Revenue growth over the past year has been substantial at -89.0%, although earnings growth data for the same period is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Visit website →Key Statistics
- Market Cap
- $143.08M
- P/E Ratio
- N/A
- 52-Week High
- $2.66
- 52-Week Low
- $1.13
- Avg Volume
- 417.05K
- Beta
- 2.85
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Israel
- Employees
- 74